Of the 23 Indian billionaires mentioned in the Bloomberg Billionaires Index, only one saw a reduction in net worth, with the companies owned by most of them outperforming the Nifty 50 index by a big margin.
Additional levy to eat into Rs 6,000-crore income of top promoters
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
This analysis is based on the quarterly earnings for 724 companies.
Samvat 2070 was a great year for top Indian conglomerates in the stock markets.
Sun maintained it would retain the best of both organisations to build a global pharma company.
US country head, key departmental heads leave; more likely to follow.
Top ten billionaires in India.
Sun-Ranbaxy are keen to complete the merger process.
The challenge of merging Ranbaxy into the company has not been factored in.
Natco Pharma, Wockhardt and Marksans have rallied between 50 and 70 per cent in the year till date.
Stocks of companies having operations and exports to Europe were the top losers.
Sun Pharma stock has appreciated at 35% a year for 20 years
FDA allows Teva to launch Nexium generic; Cipla, which supplies formulation, to gain
The S&P BSE Sensex has rallied about 28 per cent in 2014, after formation of a stable government at the Centre.
Mergers are not just about balance sheets or marketing synergies; they are also about those who make the synergies real.
Investors turn their attention to export-driven sectors.
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
FIIs have offloaded stocks worth Rs 13,110 crore
BSE-200 companies's list shows that 96 companies had woman directors.
The rise in India Inc's market value was led by asset-light firms.
Data also show that several other leading domestic pharma companies have recalled their products from the US
As part of the charm offensive, New Delhi has invited global regulators -- including the FDA -- to visit Indian production units to get first-hand evidence of measures taken to ensure the quality of locally manufactured generics.
Corporate India's earnings in the past two quarters were largely driven by the rupee's sharp fall versus the dollar in the second quarter of this financial year.
Sun Pharmaceutical Industries will take a call on whether to shut Ranbaxy's troubled factories or make changes in the top management of the latter only after its $4-billion acquisition deal is complete.
Generic drugmakers cannot be sued under state law for adverse reactions to their products.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
Payments banks will mainly deal in remittance services and accept deposits of up to Rs 1 lakh.
Dilip Shanghvi has never tried to be everything to everybody.
USL is already contesting a Karnataka High Court order.
Ranbaxy did its maiden public issue in 1973.
Dilip Shanghvi founded Sun Pharma in 1983.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
A majority of India's billionaires gained wealth in the last one year in spite of the stock market decline.
T N Ninan lists a few David-Goliath encounters in the Indian markets, all of which make life interesting, though difficult if you are an investor looking for the next multi-bagger.
Few top honchos of India Inc did very well in 2014.
